Literature DB >> 22265660

Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb.

Lisa Glasl1, Karina Kloos, Florian Giesert, Anne Roethig, Barbara Di Benedetto, Ralf Kühn, Jingzhong Zhang, Ulrich Hafen, Julia Zerle, Andreas Hofmann, Martin Hrabé de Angelis, Konstanze F Winklhofer, Sabine M Hölter, Daniela M Vogt Weisenhorn, Wolfgang Wurst.   

Abstract

Parkinson's Disease (PD) is the most common neurodegenerative movement disorder. Autosomal-recessive mutations in the mitochondrial protein kinase PINK1 (PTEN-induced kinase 1) account for 1-2% of the hereditary early-onset cases. To study the mechanisms underlying disease development, we generated Pink1-deficient mice. In analogy to other genetic loss-of-function mouse models, Pink1(-/-) mice did not show morphological alterations in the dopaminergic system. As a consequence, no gross motor dysfunctions were observed indicating that these mice do not develop the cardinal symptoms of PD. Nonetheless, symptoms which develop mainly before bradykinesia, rigidity and resting tremor were clearly evident in Pink1-deficient mice. These symptoms were gait alterations and olfactory dysfunctions. Remarkably in the glomerular layer of the olfactory bulb the density of serotonergic fibers was significantly reduced. Concerning mitochondrial morphology, neurons in Pink1(-/-) mice had less fragmented mitochondria. In contrast, upon acute knock-down of Pink1 increased mitochondrial fragmentation was observed in neuronal cultures. This fragmentation was, however, evened out within days. Taken together, we demonstrate that Pink1-deficient mice exhibit behavioral symptoms of early phases of PD and present systematic experimental evidence for compensation of Pink1-deficiency at the cellular level. Thus, Pink1-deficient mice represent a model for the early phases of PD in which compensation may still impede the onset of neurodegeneration. Consequently, these mice are a valuable tool for studying Pink1-related PD development, as well as for searching for reliable PD biomarkers.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265660     DOI: 10.1016/j.expneurol.2012.01.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  21 in total

1.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

Review 2.  Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.

Authors:  Jaclyn Nicole Le Grand; Laura Gonzalez-Cano; Maria Angeliki Pavlou; Jens C Schwamborn
Journal:  Cell Mol Life Sci       Date:  2014-11-18       Impact factor: 9.261

3.  Characterization of early-onset motor deficits in the Pink1-/- mouse model of Parkinson disease.

Authors:  Cynthia A Kelm-Nelson; Alexander F L Brauer; Kelsey J Barth; Jacob M Lake; Mackenzie L K Sinnen; Forrest J Stehula; Cagla Muslu; Roberta Marongiu; Michael G Kaplitt; Michelle R Ciucci
Journal:  Brain Res       Date:  2017-12-08       Impact factor: 3.252

Review 4.  Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.

Authors:  Bianca Marchetti; Cataldo Tirolo; Francesca L'Episcopo; Salvatore Caniglia; Nunzio Testa; Jayden A Smith; Stefano Pluchino; Maria F Serapide
Journal:  Aging Cell       Date:  2020-02-12       Impact factor: 9.304

5.  Primary cilia and SHH signaling impairments in human and mouse models of Parkinson's disease.

Authors:  Sebastian Schmidt; Malte D Luecken; Dietrich Trümbach; Sina Hembach; Kristina M Niedermeier; Nicole Wenck; Klaus Pflügler; Constantin Stautner; Anika Böttcher; Heiko Lickert; Ciro Ramirez-Suastegui; Ruhel Ahmad; Michael J Ziller; Julia C Fitzgerald; Viktoria Ruf; Wilma D J van de Berg; Allert J Jonker; Thomas Gasser; Beate Winner; Jürgen Winkler; Daniela M Vogt Weisenhorn; Florian Giesert; Fabian J Theis; Wolfgang Wurst
Journal:  Nat Commun       Date:  2022-08-16       Impact factor: 17.694

6.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Authors:  Jason R Cannon; Kindiya D Geghman; Victor Tapias; Thomas Sew; Michelle K Dail; Chenjian Li; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2012-11-12       Impact factor: 5.330

Review 7.  Parkinson's disease: experimental models and reality.

Authors:  Peizhou Jiang; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-11-18       Impact factor: 17.088

8.  Impaired sense of smell in a Drosophila Parkinson's model.

Authors:  Simone Poddighe; Krishna Moorthi Bhat; Maria Dolores Setzu; Paolo Solla; Anna Maria Angioy; Roberto Marotta; Roberta Ruffilli; Francesco Marrosu; Anna Liscia
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

9.  A critical period for postnatal adaptive plasticity in a model of motor axon miswiring.

Authors:  Michaela S Helmbrecht; Heidi Soellner; Maria A Castiblanco-Urbina; Stefan Winzeck; Julia Sundermeier; Fabian J Theis; Karim Fouad; Andrea B Huber
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

10.  PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.

Authors:  Graziella Madeo; Tommaso Schirinzi; Giuseppina Martella; E Claudio Latagliata; Francesca Puglisi; Jie Shen; Enza Maria Valente; Mauro Federici; Nicola B Mercuri; Stefano Puglisi-Allegra; Paola Bonsi; Antonio Pisani
Journal:  Mov Disord       Date:  2013-10-25       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.